ERIS Lifesciences Ltd is engaged in the business of manufacture and marketing of pharmaceutical products.
Financial Results:
ERIS Lifesciences Ltd reported Revenues for Q2FY25 of ₹741.00 Crores up from ₹505.00 Crore year on year, a rise of 46.73%.
Total Expenses for Q2FY25 of ₹616.00 Crores up from ₹382.00 Crores year on year, a rise of 61.26%.
Consolidated Net Profit of ₹96.00 Crores down 21.31% from ₹122.00 Crores in the same quarter of the previous year.
The Earnings per Share is ₹6.73, down 25.80% from ₹9.07 in the same quarter of the previous year.